1088 related articles for article (PubMed ID: 32603972)
21. Injury markers but not amyloid markers are associated with rapid progression from mild cognitive impairment to dementia in Alzheimer's disease.
van Rossum IA; Visser PJ; Knol DL; van der Flier WM; Teunissen CE; Barkhof F; Blankenstein MA; Scheltens P
J Alzheimers Dis; 2012; 29(2):319-27. PubMed ID: 22233766
[TBL] [Abstract][Full Text] [Related]
22. CSF levels of the BACE1 substrate NRG1 correlate with cognition in Alzheimer's disease.
Mouton-Liger F; Dumurgier J; Cognat E; Hourregue C; Zetterberg H; Vanderstichele H; Vanmechelen E; Bouaziz-Amar E; Blennow K; Hugon J; Paquet C
Alzheimers Res Ther; 2020 Jul; 12(1):88. PubMed ID: 32690068
[TBL] [Abstract][Full Text] [Related]
23. ADAM10 plasma levels predict worsening in cognition of older adults: a 3-year follow-up study.
Oliveira Monteiro MPA; Salheb Oliveira DSM; Manzine PR; Crispim Nascimento CM; Dos Santos Orlandi AA; de Oliveira Gomes GA; Dos Santos Orlandi F; Zazzetta MS; Pott-Junior H; Cominetti MR
Alzheimers Res Ther; 2021 Jan; 13(1):18. PubMed ID: 33419480
[TBL] [Abstract][Full Text] [Related]
24. Plasma MMP-9 Levels as the Future Risk of Conversion to Dementia in ApoE4-Positive MCI Patients: Investigation Based on the Alzheimer's Disease Neuroimaging Initiative Database.
Abe K; Chiba Y; Ide K; Yoshimi A; Asami T; Suda A; Odawara T; Hishimoto A
J Prev Alzheimers Dis; 2022; 9(2):331-337. PubMed ID: 35543007
[TBL] [Abstract][Full Text] [Related]
25. Erlangen Score as a tool to predict progression from mild cognitive impairment to dementia in Alzheimer's disease.
Baldeiras I; Santana I; Leitão MJ; Vieira D; Duro D; Mroczko B; Kornhuber J; Lewczuk P
Alzheimers Res Ther; 2019 Jan; 11(1):2. PubMed ID: 30611311
[TBL] [Abstract][Full Text] [Related]
26. Longitudinal plasma phosphorylated tau 181 tracks disease progression in Alzheimer's disease.
Chen SD; Huang YY; Shen XN; Guo Y; Tan L; Dong Q; Yu JT;
Transl Psychiatry; 2021 Jun; 11(1):356. PubMed ID: 34120152
[TBL] [Abstract][Full Text] [Related]
27. Matrix metalloproteinase 10 is linked to the risk of progression to dementia of the Alzheimer's type.
Martino Adami PV; Orellana A; García P; Kleineidam L; Alarcón-Martín E; Montrreal L; Aguilera N; Espinosa A; Abdelnour C; Rosende-Roca M; Pablo Tartari J; Vargas L; Mauleón A; Esteban-De Antonio E; López-Cuevas R; Dalmasso MC; Campos Martin R; Parveen K; Andrade Fuentes VM; Amin N; Ahmad S; Ikram MA; Lewczuk P; Kornhuber J; Peters O; Frölich L; Rüther E; Wiltfang J; Tarraga L; Boada M; Maier W; de Rojas I; Cano A; Sanabria A; Alegret M; Hernández I; Marquié M; Valero S; van Duijn CM; Wagner M; Jessen F; Schneider A; Sáez Goñi ME; González Pérez A; Ruiz A; Ramírez A
Brain; 2022 Jul; 145(7):2507-2517. PubMed ID: 35088840
[TBL] [Abstract][Full Text] [Related]
28. Associations of cerebrospinal fluid complement proteins with Alzheimer's pathology, cognition, and brain structure in non-dementia elderly.
Li M; Ma YH; Guo Y; Liu JY; Tan L;
Alzheimers Res Ther; 2024 Jan; 16(1):12. PubMed ID: 38238858
[TBL] [Abstract][Full Text] [Related]
29. Alzheimer's Disease Biomarkers and Future Decline in Cognitive Normal Older Adults.
Dumurgier J; Hanseeuw BJ; Hatling FB; Judge KA; Schultz AP; Chhatwal JP; Blacker D; Sperling RA; Johnson KA; Hyman BT; Gómez-Isla T
J Alzheimers Dis; 2017; 60(4):1451-1459. PubMed ID: 29036824
[TBL] [Abstract][Full Text] [Related]
30. Predicting and Tracking Short Term Disease Progression in Amnestic Mild Cognitive Impairment Patients with Prodromal Alzheimer's Disease: Structural Brain Biomarkers.
Marizzoni M; Ferrari C; Jovicich J; Albani D; Babiloni C; Cavaliere L; Didic M; Forloni G; Galluzzi S; Hoffmann KT; Molinuevo JL; Nobili F; Parnetti L; Payoux P; Ribaldi F; Rossini PM; Schönknecht P; Salvatore M; Soricelli A; Hensch T; Tsolaki M; Visser PJ; Wiltfang J; Richardson JC; Bordet R; Blin O; Frisoni GB;
J Alzheimers Dis; 2019; 69(1):3-14. PubMed ID: 29914031
[TBL] [Abstract][Full Text] [Related]
31. Does serum uric acid act as a modulator of cerebrospinal fluid Alzheimer's disease biomarker related cognitive decline?
Ye BS; Lee WW; Ham JH; Lee JJ; Lee PH; Sohn YH;
Eur J Neurol; 2016 May; 23(5):948-57. PubMed ID: 26917248
[TBL] [Abstract][Full Text] [Related]
32. Discordant amyloid-β PET and CSF biomarkers and its clinical consequences.
de Wilde A; Reimand J; Teunissen CE; Zwan M; Windhorst AD; Boellaard R; van der Flier WM; Scheltens P; van Berckel BNM; Bouwman F; Ossenkoppele R
Alzheimers Res Ther; 2019 Sep; 11(1):78. PubMed ID: 31511058
[TBL] [Abstract][Full Text] [Related]
33. Association of APOE gene with longitudinal changes of CSF amyloid beta and tau levels in Alzheimer's disease: racial differences.
Xu C; Xiao D; Su BB; Saveron JM; Gamez D; Navia RO; Wang N; Roy U; Adjeroh DA; Wang K;
Neurol Sci; 2024 Mar; 45(3):1041-1050. PubMed ID: 37759100
[TBL] [Abstract][Full Text] [Related]
34. Analysis of matrix metallo-proteases and the plasminogen system in mild cognitive impairment and Alzheimer's disease cerebrospinal fluid.
Hanzel CE; Iulita MF; Eyjolfsdottir H; Hjorth E; Schultzberg M; Eriksdotter M; Cuello AC
J Alzheimers Dis; 2014; 40(3):667-78. PubMed ID: 24531161
[TBL] [Abstract][Full Text] [Related]
35. Longitudinal change of biomarkers in cognitive decline.
Lo RY; Hubbard AE; Shaw LM; Trojanowski JQ; Petersen RC; Aisen PS; Weiner MW; Jagust WJ;
Arch Neurol; 2011 Oct; 68(10):1257-66. PubMed ID: 21670386
[TBL] [Abstract][Full Text] [Related]
36. CSF cutoffs for MCI due to AD depend on APOEε4 carrier status.
Marizzoni M; Ferrari C; Babiloni C; Albani D; Barkhof F; Cavaliere L; Didic M; Forloni G; Fusco F; Galluzzi S; Hensch T; Jovicich J; Marra C; Molinuevo JL; Nobili F; Parnetti L; Payoux P; Ranjeva JP; Ribaldi F; Rolandi E; Rossini PM; Salvatore M; Soricelli A; Tsolaki M; Visser PJ; Wiltfang J; Richardson JC; Bordet R; Blin O; Frisoni GB
Neurobiol Aging; 2020 May; 89():55-62. PubMed ID: 32029236
[TBL] [Abstract][Full Text] [Related]
37. Cerebrospinal fluid biomarkers distinguish postmortem-confirmed Alzheimer's disease from other dementias and healthy controls in the OPTIMA cohort.
Seeburger JL; Holder DJ; Combrinck M; Joachim C; Laterza O; Tanen M; Dallob A; Chappell D; Snyder K; Flynn M; Simon A; Modur V; Potter WZ; Wilcock G; Savage MJ; Smith AD
J Alzheimers Dis; 2015; 44(2):525-39. PubMed ID: 25391385
[TBL] [Abstract][Full Text] [Related]
38. T1rho MRI and CSF biomarkers in diagnosis of Alzheimer's disease.
Haris M; Yadav SK; Rizwan A; Singh A; Cai K; Kaura D; Wang E; Davatzikos C; Trojanowski JQ; Melhem ER; Marincola FM; Borthakur A
Neuroimage Clin; 2015; 7():598-604. PubMed ID: 25844314
[TBL] [Abstract][Full Text] [Related]
39. The Associations of Phosphorylated Tau 181 and Tau 231 Levels in Plasma and Cerebrospinal Fluid with Cognitive Function in Alzheimer's Disease: A Systematic Review and Meta-Analysis.
Li Z; Fan Z; Zhang Q
J Alzheimers Dis; 2024; 98(1):13-32. PubMed ID: 38339929
[TBL] [Abstract][Full Text] [Related]
40. Changes in Plasma Amyloid and Tau in a Longitudinal Study of Normal Aging, Mild Cognitive Impairment, and Alzheimer's Disease.
Chen TB; Lai YH; Ke TL; Chen JP; Lee YJ; Lin SY; Lin PC; Wang PN; Cheng IH
Dement Geriatr Cogn Disord; 2019; 48(3-4):180-195. PubMed ID: 31991443
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]